AstraZeneca’s Zurampic approved in the EU for patients with gout
The European Commission (EC) has granted marketing authorisation for AstraZeneca’s Zurampic (lesinurad) 200mg for patients with gout. Specifically, Zurampic is approved in combination with a xanthine oxidase inhibitor (XOI) for the adjunctive treatment of hyperuricemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid (sUA) levels with an adequate dose of an XOI alone.
Click on this link for more information.
